Big Pharma didn’t rest Thursday, with Celgene, Sanofi-Aventis and AstraZeneca among the big names reporting earnings. A deal between Stryker and Boston Scientific and Sanofi and BMP Sunstone also made the headlines, as did some…
French pharmaceutical giant Sanofi-Aventis says its multiple sclerosis drug teriflunomide significantly cut relapses in patients who took the once-daily oral treatment.
Continue reading Sanofi Says MS Drug Redu…
After a long wait, the FDA has OK’d Novartis’s Gilenya as a first-line treatment for relapsing forms of multiple sclerosis — the disease’s most common form. MS affects over 400,000 Americans and more than 2.1 million people wo…